Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium bifidum f35
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium bifidum F35 is a specific strain of Bifidobacterium bifidum, a Gram-positive, strictly anaerobic bacterium commonly found in the human gastrointestinal tract. As a probiotic, B. bifidum strains are known for their beneficial effects on gut health, including modulation of the intestinal microbiota and enhancement of mucosal barrier function. The F35 strain has been studied for its fermentation characteristics and potential health benefits when used in food products such as fermented hazelnut milk[1][3][9]. Like other B. bifidum strains, it may exert anti-inflammatory effects and help restore microbial balance in the gut[2][5]. Probiotic preparations containing Bifidobacterium species are primarily indicated for prevention or treatment of gastrointestinal disorders such as diarrhea, constipation, irritable bowel syndrome (IBS), and inflammatory bowel disease (IBD)[5][6].
- Other names
- 两歧双歧杆菌F35
Beyond the preview
Go deeper on bifidobacterium bifidum f35.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium bifidum f35.